Citigroup Downgrades Sabra Health Care REIT to Neutral, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 92.7%

Neg 92.7% Neu 0% Pos 0%

Citigroup analyst Nick Joseph downgrades Sabra Health Care REIT (NASDAQ:SBRA) from Buy to Neutral and lowers the price target from $24 to $19.